Siti Mariam Abdul Wahab
Ibrahim Jantan
Md. Areeful Haque
Laiba Arshad- Drug and Herbal Research Center, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
The use of anti-inflammatory natural products to treat inflammatory disorders for cancer prevention and therapy is an appealing area of interest in the last decades. Annona muricata L. is one of the many plant extracts that have been explored owing to their anti-inflammatory and anticancer effects. Different parts of A. muricata especially the leaves have been used for various ethnomedicinal purposes by traditional healers to treat several diseases including cancer, inflammation, diabetes, liver diseases, and abscesses. Some of these experience-based claims on the use of the plant have been transformed into evidence-based information by scientific investigations. The leaves of the plant have been extensively investigated for its diverse pharmacological aspects and found eminent for anti-inflammatory and anticancer properties. However, most studies were not on the bioactive isolates which were responsible for the activities but were based on crude extracts of the plant. In this comprehensive review, all significant findings from previous investigations till date on the leaves of A. muricata, specifically on their anti-inflammatory and anticancer activities have been compiled. The toxicology of the plant which has been shown to be due to the presence of neurotoxic annaceous acetogenins and benzyltetrahydro-isoquinoline alkaloids has also been updated to provide recent information on its safety aspects. The present knowledge of the plant has been critically assessed, aimed at providing direction toward improving its prospect as a source of potential anti-inflammatory and anticancer agents. The analysis will provide a new path for ensuring research on this plant to discover new agents to treat inflammatory diseases and cancer. Further in vitro and in vivo studies should be carried out to explore the molecular mechanisms underlying their anti-inflammatory responses in relation to anticancer activity and more detail toxicity study to ensure they are safe for human consumption. Sufficient preclinical data and safety data generated will allow clinical trials to be pursued on this plant and its bioactive compounds.
Introduction
Inflammation, owing to central element of innate immunity and inflammatory response serve as a protective mechanism emerged in higher animals in order to defend them against injury and infection. In reaction to any tissue damage, a multifactorial network of chemical signals is initiated in the human body which keep the host body response and repair the impaired tissue. This multifactorial network encompasses activation and migration of different inflammatory cells i.e., monocytes, neutrophils, and eosinophils from the venous system to sites of injury. The coordination of the recruitment of aforementioned inflammatory cells to sites of tissue injury and to the provisional extracellular matrix (ECM) involves a four-step mechanism. The first step is the activation of adhesion molecules such as L-, P-, and E-selectin, expedite rolling along the vascular endothelium. Next step is the triggering of signals mediated by leukocyte-activating molecules and cytokines leading to activation and upregulation of leukocyte integrins. Thirdly, neutrophils are immobilized on the surface of the vascular endothelium by tight adhesion through α4β1 and α4β7 integrins further binding to endothelial vascular cell-adhesion molecule-1 (VCAM-1) and MadCAM-1, respectively. Lastly, the transmigration of the cells to the site of injury through the endothelium is supposedly mediated by extracellular proteases, such as matrix metalloproteinases (MMPs) (Chettibi et al., 1999). In the main, inflammation is segregated as acute inflammation and chronic inflammation. The acute inflammatory phase is characterized by increased in blood flow, aggregation of fluid, different cytokines and leukocytes and vascular permeability (Feghali and Wright, 1997). Nonetheless it resides for short time and is usually self-limiting because of the production of anti-inflammatory cytokines followed by pro-inflammatory cytokines ultimately resulting in tissue remodeling and normal tissue homeostasis. Notwithstanding, if there is unabating inflammation or if the system fails to return to normal homeostasis it eventually leads to chronic inflammation which is identified as a root cause in the development of a variety of chronic inflammatory and immune-related diseases (Arshad et al., 2017a). Chronic inflammation is correlated to the progression of human diseases such as arthritis, cancer, allergy, infectious diseases, arteriosclerosis, and autoimmune disorders (Medzhitov, 2008). Most of the immune system disorders are usually described by overactivity of the immune cells or abnormally low activity of the immune system. The body attacks and damages its own tissues, a condition known as acquired immune system reaction (autoimmune diseases) in cases of hyperactivity of immune system while immune deficiency diseases decrease the body's ability to fight invading pathogens, causing vulnerability to infections. Cancer, rheumatoid arthritis, Type 1 diabetes, systemic lupus erythematosus, tuberculosis and atherogenesis, are among the most common diseases due to suppression of the immune functions.
Immunoediting which describes the relation between immune response and tumor development occurs in three phases. During the elimination phase acute inflammatory response induced by innate and adaptive immune system occurs to recognize and eliminate the early-generated tumor cells by induction of apoptosis. Next, the tumor cells start to resist the strong immune surveillance and shift into the equilibrium phase between the tumor proliferation and apoptosis. In the escape phase, tumor cells become less immunogenic and able to evade the immune control (Mohamed et al., 2017). Chronic inflammation (e.g., chronic inflammatory bowel diseases, chronic gastritis, prostatitis, ulcerative colitis) may increase the incidence of cancer generation. Accumulation of bioactive cytokines, chemokines, ROS and growth factors by the immune cells will induce mutation development and transition of the normal cells into abnormal tumor cells (Balkwill, 2009). The proliferation of normal cells is enhanced during tissue injury associated with wounding, along with the regeneration of tissue, as the invading pathogen is removed, proliferation, and inflammation abated and the repair is completed. On the other hand, proliferating cells that endure DNA damage continue to proliferate in microenvironments and growth factors support their growth. Eventually, the tumor microenvironment is said to be largely concentrated with inflammatory cells, which is considered a crucial element in the neoplastic process, further stimulating proliferation, survival, and migration. Additionally, tumor cells are also assimilated with some of the signaling molecules of the innate immune system, such as chemokines, selectins, and their receptors for invasion, migration, and metastasis (Dvorak, 1986).
Natural products especially plant-derived compounds have been classified as a significant class of novel immunomodulators particularly as potent anti-inflammatory and anticancer agents. The anti-inflammatory and anticancer properties of plant-based therapeutics have attracted the interest of researchers as they provide alternative strategies to manage several infectious and debilitating diseases. A number of plant extracts have been suggested as potent immunomodulators with promising anti-inflammatory and anticancer properties such as Annona muricata L., Catharanthus roseus (L.) G. Don, Camptotheca accuminata Decne., Centella asiatica (L.) Urb., Ipomoea batatas (L.) Lam, Phyllanthus amarus Schumach. & Thonn., Phyllanthus niruri L., Picrorhiza scrophulariiflora Pennell, Trigonella foenum graecum L., and Zingiber zerumbet (L.) Roscoe ex Sm. (da Rocha et al., 2001; Jantan et al., 2015; Ahmad et al., 2016; Ilangkovan et al., 2016; Laksmitawati et al., 2016; Haque and Jantan, 2017; Haque et al., 2017a). Furthermore, phytochemicals such as alkaloids, terpenoids, polysaccharides, lactones, flavonoids, carotenoids, and glycosides as well as essential oils isolated from several plants have also been shown to exhibit potential anti-inflammatory and anticancer effects (Jantan et al., 2015; Arshad et al., 2017b; Haque and Jantan, 2017; Haque et al., 2017a,b; Mohamed et al., 2017). The plant extracts and their active constituents with anti-inflammatory potential serve as natural resources and may provide us with valuable entities to develop novel anti-inflammatory agents to be used as supplements or adjuvants with the present therapeutic modalities for chemotherapy. This review is to provide an updated overview of the potential anti-inflammatory and anticancer roles of the leaves of Annona muricata L., their underlying mechanisms of modulating the immune-associated molecular targets, and critically assessed its importance in providing new leads for the development of new anti-inflammatory and anticancer agents. In addition, phytochemistry, and toxicological information have also been included to correlate its efficacy and clarify its safety profile.
Distribution and Taxonomy
Annona muricata is widely known as soursop due to the sour and sweet taste of its fruit. It is also known as prickly custard apple due to its taste. The fruit is locally referred as durian belanda. In Indonesia, the plant is called sirsak or nangka belanda, while it is known as graviola in Portuguese and guanabana in Latin American. It is also recognized by other indigenous names such as annone, anona, graviola, araticum grande, araticum-manso, coronsol, corossol épineux, grand corossol, coração-de-rainha, guanábana, guanábano, gurúsulu, jaca-do-pará, kaoraosaly' jaca-de-pobre, cachiman épineux, mkononono, anoda, pumo, puntar waihia, quanabana, saput, sauersack, stachelannone, taggannona, and zuurzak. This plant has the taxonomic classification of the kingdom of Plantae, the division of Angiosperms (Magnoliophyta), the class of Magnolids, the order of Magnoliales, the family of Annonaceae, the genus of Annona and the species of A. muricata L. (Pinto et al., 2005a; Gavamukulya et al., 2017). The accepted full name of this species is A. muricata L. with other synonyms; A. muricata var. borinquensis Morales, A. muricata f. mirabilis R.E.Fr., A. bonplandiana Kunth, A. cearaensis Barb. Rodr., A. macrocarpa Wercklè and Guanabanus muricatus M. Gómez. The Annonaceae family consists of approximately 130 genera and 2300 species, while the genus Annona comprises over 70 species among which A. muricata is the most widely grown (Leboeuf et al., 1980; Mishra et al., 2013; Coria-Téllez et al., 2016). A. muricata is endemic to the warmest areas of the tropics of South and Central America and the Caribbean. It is now widely found in tropical and subtropical regions of Central and South America, Western Africa, and Southeast Asia at the altitudes below 1,200 m above sea level with temperature ranging from 25 to 28°C and relative humidity between 60 and 80% and have the annual rainfall above 1500 mm (Adewole and Caxton-Martins, 2006; Coria-Téllez et al., 2016). It is a tree 5–8 m in height, 15–83 cm in diameter and features an open, roundish canopy with large, glossy, dark green leaves (González et al., 2004). The tree tends to bloom and fruit most of the year, but there are more defined seasons depending on the altitude (Pinto et al., 2005a). Its fruits are edible, heart-shaped, green in color and 15–20 cm in diameter. The flesh is white and creamy with a characteristic aroma and flavor. Each fruit may contain 55-170 black seeds when fresh and they turn light brown when dry (Awan et al., 1980). Figure 1 refers the various plant parts of A. muricata. The full scientific names, synonyms, vernacular/ common names, classification, distributional range, and consumed parts of A. muricata are summarized in Table 1.
Figure 1. Annona muricata L. (A) Whole plant (B) Leaves (C) Flowers (D) Fruits (E) Seeds.
Table 1. General information of Annona muricata L.
Traditional Values
Different parts of A. muricata are widely used in traditional medicine of many countries to cure various ailments and diseases. The natives of Malaysia apply the leaf juice of a mixture of A. muricata, A. squamosa L. and Hibiscus rosa-sinensis L. on the head to protect against fainting, and they also use the A. muricata leaves to treat cutaneous (external) and internal parasites (Ong and Norzalina, 1999). The leaves have also been used to treat cystitis, diabetes, headaches, and insomnia (Adewole and Caxton-Martins, 2006; de Souza et al., 2009; Mishra et al., 2013). The decoction of the leaves is applied topically for its anti-rheumatic and neuralgic effects, and to reduce abscesses (Adewole and Caxton-Martins, 2006; de Souza et al., 2009; Mishra et al., 2013). The leaves are used in the bath to cure skin diseases in the Caribbean islands, Indonesia as well as in the South Pacific countries (Longuefosse and Nossin, 1996; Boulogne et al., 2011). In Ecuador, Mauritius, and New Guinea, the application of the A. muricata leaves is local on the pain site (Tene et al., 2007; Rai et al., 2009; Sreekeesoon and Mahomoodally, 2014). Decoctions of A. muricata leaves are used as analgesics in Brazil, Martinique, Mexico and Nicaragua (Longuefosse and Nossin, 1996; Ross, 2010), while in Benin, the Caribbean, Cuba, and Mexico, it is used to reduce colds, flu, and asthma (Joyeux et al., 1995; Beyra et al., 2004; Kossouoh et al., 2007; Haiat and Bucay, 2009). The importance of A. muricata leaves to treat malaria is very crucial in tropical countries such as Cameroon, Togo, and Vietnam (Ross, 2010; Boyom et al., 2011; Tan et al., 2015). In Ghana, A. muricata and some other plants are decocted into a mixture and used in bath for feminine hygiene (Asase et al., 2012).
Table 2 enlists the traditional medicinal uses that have been reported for the leaves of A. muricata, together with the regions in which they are used as well as the mode of uses. Besides the wide array of the ethnopharmacological values of the leaves of A. muricata, the juicy flesh-fruit of the soursop is a remedy for rheumatism, arthritic pain, fever, neuralgia, heart, and liver diseases, diarrhea, dysentery, malaria, parasites, skin rashes, and worms as well as increasing breast milk after childbirth (de Lima and Alves, 2011; Hajdu and Hohmann, 2012; Moghadamtousi et al., 2015a). In India, the roots, bark and leaves of A. muricata are claimed to exhibit antiphlogistic and anthelmintic activities while the flowers and fruits of the plant are applied to treat catarrh (Watt and Breyer-Brandwijk, 1962; Adewole and Ojewole, 2009). The seeds are used as an anti-anthelmintic against external and internal worms and parasites. A. muricata is employed in tropical Africa as insecticidal and pesticidal agents besides being used for the treatment of coughs, pain and skin diseases (Moghadamtousi et al., 2015a). The leaves, seeds, unripe fruits and roots of A. muricata are traditionally used as biopesticides, bioinsecticides and topical insect repellents and showed significant effectiveness among other pests in Latin America. The aqueous extract of A. muricata is used to control lepidopteran larvae, aphids and thrips, among others (Brechelt, 2004; Leatemia and Isman, 2004; Isman and Akhtar, 2007). In addition, the leaves, bark, and roots of A. muricata have been used for its anti-inflammatory, hypotensive, sedative, hypoglycemic, smooth muscle relaxant, and antiplasmodic effects (Adewole and Ojewole, 2009; Mishra et al., 2013). Besides the traditional medicinal uses, A. muricata is also used in other fields, for instance, the fruits are widely used in the food industries in the making of syrups, beverages, candy, ice creams and shakes (Wu et al., 1995a; Jaramillo-Flores and Hernandez-Sanchez, 2000).
Table 2. Traditional uses of the leaves of Annona muricata L.
Phytochemistry
Phytochemical studies have been extensively carried out on different parts of A. muricata and till date, 212 secondary metabolites have been isolated and identified, such as acetogenins, alkaloids, phenolic compounds, and megastigmanes (Leboeuf et al., 1980; Yang et al., 2015; Coria-Téllez et al., 2016). A. muricata leaves have been reported to be a rich source of annonaceous acetogenins, a unique group of derivatives of long chain fatty acids derived from the polyketide pathway that belong to the family of Annonaceae (Sun et al., 2016). Thorough investigations have been carried out on the leaves of A. muricata as the leaves are the most utilized parts used for a wide array of ethnomedicinal uses. Acetogenins are the most predominant bioactive compounds of Annonaceace family, as well as of A. muricata. In the previous phytochemical investigations, more than 120 acetogenins have been reported from the leaves, stems, bark, seeds, pulp, and fruit peel of A. muricata, and, to date, approximately 46 acetogenins have been identified from the leaves. Wu and co-workers have isolated six annonaceous acetogenins from 95% ethanol extract of the leaves of A. muricata by subjecting the active fraction of the extract to repeated flash chromatography and high performance liquid chromatography (HPLC) to yield isolates namely, annomuricin A, annomuricin B, annomuricin C, muricatocin A, muricatocin B, and muricatocin C (Wu et al., 1995a,b,c). Zeng et al. (1996) isolated annopentocin A, annopentocin B, annopentocin C, cis-annomuricin-D-ones and trans-annomuricin-D-ones from the leaves of A. muricata (Zeng et al., 1996). Annonacin, annonacin A, annonacin B, annonacin-10-one, muricatalicin and muricatalin have been isolated and identified by Yu et al. (1997). Further investigation on the A. muricata leaf extract yielded annonaceous acetogenins, spectroscopically identified as annomuricine, muricoreacin, murihexocin C, and muricapentocin (Kim et al., 1998a,b). Further studies led to the isolation of annonacin, annonacinone, annocatalin, cis-corossolone, solamin, and corossolone (Liaw et al., 2002). Recent investigation conducted by Moghadamtousi et al. (2015c) on the ethyl acetate extract of A. muricata leaves afforded annomuricin E by using column chromatography approach. Notably, acetogenin is a long aliphatic chain of 35–38 carbons bonded to a γ-lactone α ring and terminally substituted by β-unsaturated methyl, in some cases, it is a ketolactone, with one or two tetrahydrofurans (THF) located along the hydrocarbons chain and a determined number of oxygen groups (hydroxyl, acetoxyls, ketones, epoxy). The previously identified acetogenins in A. muricata are mainly of mono-THF ring, although acetogenins have also been reported with two adjacent or nonadjacent THF rings. Moreover, acetogenins are linear and may have one or two epoxy groups (Coria-Téllez et al., 2016). Annonacin was the most abundant acetogenin isolated from the leaves of A. muricata (Champy et al., 2009).
Alkaloids are a diverse group of naturally occurring secondary compounds derived from amino acids or the process of transamination (Dey et al., 2017). Till date, around 22 alkaloids have been reported from A. muricata leaves. Anomurine and anomuricine, the isoquinoleic alkaloids were isolated and reported by Leboeuf et al. (1980). The chloroform extraction of A. muricata leaves yielded a crude extract with 0.125% of total alkaloids, which was later separated into nonphenolic and phenolic parts and subjected to column chromatography over silica gel. The nonphenolic fraction afforded aporphine alkaloids identified as anonaine, isolaureline, and xylopine, while the phenolic fraction led to the isolation of coclaurine, the benzyltetrahydroisoquinoline alkaloid (Fofana et al., 2011). Fofana et al. (2011) conducted further investigation on the alkaloid content of A. muricata leaves using chromatography over a column of silica gel. The alkaloids were eluted by various ratios of benzene and ethanol solvent system 99:1, 98:2, 95:5, and 90:10, yielded N-methylcoclaurine, asimilobin, remerine, isoboldine, and liriodenine. Subsequently, Matsushige et al. (2012b) isolated annonamine, (R)-O,O-dimethylcoclaurine, (S)-norcorydine and (R)-4′-O-methylcoclaurine. Based on previous investigations, reticuline and cureximine are the most abundant alkaloids in A. muricata (Leboeuf et al., 1982), and the leaves contained the highest alkaloid concentration compared to the roots, stems and fruits (Leboeuf et al., 1982; Fofana et al., 2011, 2012). Notably, isoquinoline, aporphine, and protoberberine typed-alkaloids were the most frequently isolated from the A. muricata (Mohanty et al., 2008).
Phenolic compounds are considered as the most important phytochemicals as most of them are soluble in water, since the most commonly used extract in traditional medicine is aqueous infusion (Coria-Téllez et al., 2016). Thirty-four phenolic compounds have been isolated from the leaves of A. muricata. The purification of n-butanol leaf extract of A. muricata led to the isolation of robinetin, taxifolin (+), quercetin, apigenin-6-C-glucoside, gallic acid, and luteolin 3′7-di-O-glucoside (George et al., 2012). Further investigation by Nawwar et al. (2012) resulted in the isolation of the argentinine, catechine, chlorogenic acid, epicatechine, kaempferol, kaempferol 3-O-rutinoside, quercetin 3-O-glucoside, quercetin 3-O-neohesperidoside, quercetin 3-O-robinoside, quercetin 3-O-α-rhamnosyl-(1-6)-β-sophorside, quercetin 3-O-α-rhamnosyl and quercetin-O-rutinoside. Recently, an investigation on the methanol and aqueous leaf extracts of A. muricata yielded cinnamic acid, coumaric acid, daidzein, emodin, gallocatechin, genistein, glycitein, homooorientin, isoferulic acid, and vitexin (George et al., 2015). Alongside, 14 megastigmanes, namely, annoionol A, annoionol B, annoionol C, annoionoside, vomifoliol, roseoside, turpinionoside A, citroside A, blumenol C, (+)-epiloliolide, loliolide, (1S,2S,4R)-trans-2-hydroxy-1,8-cineole β-D-glucopyranoside, (Z)-3-hexenyl β-D-glucopyranoside and rutin have also been isolated and reported to be present in the leaves of A. muricata (Matsushige et al., 2012b). Besides all the above mentioned phytochemicals, vitamins, amides, and essential oils have also been identified from the leaves of A. muricata. To date, 80 essential oils constituted mainly of sesquiterpenes derivatives have been identified in the leaves of this promising plant. All of the secondary metabolites isolated from the leaves of the A. muricata are compiled and summarized in Table 3.
Table 3. Major secondary metabolites isolated from the leaves of Annona muricata L.
Anti-Inflammatory Activity
The anti-inflammatory activity of A. muricata leaves has been reported by many studies as listed in Table 4. The in vitro study conducted by Laksmitawati et al. (2016) revealed that A. muricata leaf extract possessed anti-inflammatory activity as it inhibited the inflammatory mediators, TNF-α, IL-1β, IL-6 and nitric oxide (NO). A. muricata leaf extract exhibited a remarkable difference on the TNF-α level in LPS-induced RAW264.7 cell line as compared to the positive control (LPS-stimulated cells without the extract) and demonstrated a worthy inhibitory activity with 46.8% inhibition. The administration of 50 μg/mL of A. muricata leaf extract in RAW264.7 cells resulted in 264.69 pg/mL of the TNF-α level, which was found comparable with the negative control (normal cell) (Laksmitawati et al., 2016). A. muricata leaf extract also significantly inhibited IL-6 and NO levels in an inflammation-induced cell at respective concentrations of 50 and 75 μg/mL to 63.89% (219.13 pg/mL) and 70.67% (9.79 μM), respectively. The study demonstrated the potential of A. muricata leaf extract in treating inflammation. Likewise, Moghadamtousi et al. (2015b) reported that A. muricata leaf extract showed anti-inflammatory activity during their investigation on wound healing potential of the extract on rats with excisional wound. The immunohistochemical evaluation in this study indicated the anti-inflammatory activity of the extract by revealing the up-regulation of HSP70. The ethanol extract of A. muricata leaves exhibited notable anti-arthritic activities in complete Freund's adjuvant (CFA)-induced arthritis in rats as reported by Chan et al. (2010). A. muricata extract at all doses (3, 10, 30, and 100 mg/kg) significantly reduced the edema by 48.39, 66.67, 79.57, and 72.04%, respectively, while at higher doses (30 and 100 mg/kg) significantly suppressed TNF-α level by 42.81 and 51.82% and IL-1β level by 35.57 and 39.79%, respectively, on day 14 post-CFA injection. The effects of the extract at the higher doses in suppressing TNF-α were stronger than the effect of indomethacin (51.82%).
Table 4. Anti-inflammatory activity of A. muricata leaf extract.
In an in vivo study, different doses of A. muricata extract were assayed in carrageenan-induced inflammation and tetradecanoylphorbol acetate (TPA)-induced edema in mice. Myeloperoxidase activity (MPO) in inflamed tissue, MPO released by A-23187-stimulated rat neutrophils and NO released by murine macrophages were also determined (Quilez et al., 2015). The leaf extract at 250 and 500 mg/kg exhibited a significant edema reduction by 26.82 and 52.70%, respectively, in the carrageenan-induced edema model after the first h of observation. The study further highlighted that a single administration by oral gavage of A. muricata leaf extract at the concentration of 500 mg/kg was reported to significantly reduce the paw edema, as effective as 50 mg/kg of the standard ibuprofen. On the other hand, for the tetradecanoylphorbol acetate (TPA)-induced edema test, 56 and 78% of the edema was remarkably and dose-dependently reduced at the concentrations of 2.5 and 5 mg/ear of A. muricata leaf extract, respectively. A topical administration of the leaf extract of A. muricata notably and dose-dependently suppressed the overproduction of MPO by 92.5% of inhibition at the dose of 5 mg/ear. MPO was also reduced in activated rat neutrophils at 200 μg/ml while NO production was also dose-dependently suppressed in LPS-stimulated murine macrophages. In a nutshell, these finding revealed an outstanding anti-inflammatory properties of the extract of A. muricata leaves and directly confirmed the traditional uses of this species in treating inflammation. Analogously, another investigation reported that 1.5 mg/kg of the A. muricata leaf extract reduced 71.12% of carrageenan-induced edema in a mouse model (de Sousa et al., 2010). They suggested that the anti-inflammatory action of the plant extract was related to inhibition of one or more signaling intracellular pathways involved with the mediators (e.g., histamine, serotonin, bradykinin, substance P, and a platelet activating factor and prostaglandin). Moreover, the ethanol extract of A. muricata leaves had shown significant antinociceptive activity in a concentration-dependent manner when subjected to acetic acid-induced abdominal writhing in mice, formalin test in rats and hot plate test in mice (Hamid et al., 2012). For acetic acid-induced (0.6% acetic acid) writhing test of mice, the extract showed antinociceptive effect by significantly inhibiting the number of abdominal writhes, the potent activity was observed at a dose of 100 mg/kg. For formalin test, the administration of the extract inhibited biphasic characteristic response in the early as well as the late phase at all aforementioned doses. For hot plate test performed in mice, the extract extended the reaction time of mice (licking the paw or jumping) exposed to the hot plate when compared with control group and significantly increased the reaction time at the concentration of 100 mg/kg.
Apart from the leaves of A. muricata, the fruit has also been reported to exhibit immunomodulatory and anti-inflammatory activities. The methanol extract of fruit peel A. muricata at 6.25 and 100 μg/mL significantly suppressed the leukocytes expression of CD18/11a and exhibited 58.43 % of phagocytosis of leukocytes stimulatory activity at 100 μg/mL, comparable to the negative control. The fruit peel extract of A. muricata has potential to be used to treat health problems related to the immune system as it could modulate the innate immune system (Harun et al., 2015). Furthermore, investigation on the effect of fruit juice of A. muricata on ischemia-reperfusion injury in rats also confirmed that A. muricata fruit extract exhibited in vivo anti-inflammatory activities (Mohammed and Abbas, 2016). The anti-inflammatory effects of lyophilized fruit extract of A. muricata in mice was investigated using the carrageenan-induced rat paw edema and xylene-induced ear edema tests (Ishola et al., 2014). The time-dependent increase in paw circumference induced by carrageenan was inhibited by A. muricata treatment which was comparatively similar to that of diclofenac treated, while at 50 or 100 mg/kg pretreatment the xylene-induced ear edema was significantly reduced. The extract concentration-dependently inhibited both cyclooxygenase (COX)-1 and COX-2 activity by 39.44 and 55.71%, respectively, at 100 μg/mL.
On the contrary, Kim et al. (2016) reported the immunomostimulatory effect of standardized A. muricata leaf extract via activation of mitogen-activated protein kinase (MAPK) pathway in RAW 264.7 macrophages. The steam and ethanol extracts of A. muricata stimulated the mRNA expression of cytokines, including the pro-inflammatory cytokines, IL-1α and TNF-α, however only the steam extract up regulated inducible nitric oxide synthase (iNOS). The extracts also enhanced the production of TNF-α and nitrite, in consistence with their transcriptional expression. The authors suggested that A. muricata has the potential to be developed into an immune-boosting product for immuno-compromised patients. It is interesting to note that the results of this study contradicted the results of all previous studies which reported that the leaf extract of A. muricata possessed anti-inflammatory activity as it inhibited the inflammatory mediators. The contradicting results may be due to the use of different solvents and extraction procedures or the different chemical composition of the extracts used in the different studies. Further detailed mechanistic studies are required to ascertain the modulatory effects of the standardized A. muricata leaf extract on the immune system particularly on the pro-inflammatory mediators.
Anticancer Activity
In Vitro Anticancer Activity of Extracts of A. muricata Leaves
Extensive anticancer investigations have been conducted on A. muricata due to its reported ethnomedicinal uses against tumors and cancer (Adewole and Ojewole, 2009). Numerous lines of evidence suggest that the leaf extract of A. muricata repressed tumor growth in vivo in animal models as well as induced apoptosis of various cancer cells in vitro (Liu et al., 2016). Cytotoxicity studies on the A. muricata leaves have been accomplished on numerous cell lines. The A. muricata leaf extracts were investigated for cytotoxicity against human bladder cancer cells, K562 as well as human leukemia cancer cells, ECV304, where the results manifested a remarkable cytotoxic effects (Oviedo et al., 2009). The extract was also tested on kidney epithelial cells, VERO, stomach cancer cells, C-678 and human large lung cell carcinoma, H-460 cell lines and gave IC50 values lower than 0.00022 mg/mL for all three cell lines (Quispe et al., 2006). Subsequently, a number of cytotoxicity studies on the A. muricata leaf extract have been carried out, including cytotoxicity on histiocytic lymphoma cell line, U937, pancreatic cancer cells, FG/COLO357, breast cancer cells, MDA-MB-435S, immortalized human keratinocytes, HaCat, normal human liver cells, WRL-68 as well as human skin malignant melanoma, A375 (Ménan et al., 2006; Osorio et al., 2007; George et al., 2012; Nawwar et al., 2012; Torres et al., 2012). For the histiocytic lymphoma cell line, it was noted that the extract demonstrated considerable suppression with a LC50 value of 7.8 μg/mL. Moreover, it also demonstrated strong toxicity toward FG/COLO357 with an IC50 value of 200 μg/mL (Torres et al., 2012). George et al. (2012) reported the cytotoxic effect of n-butanolic extract of A. muricata leaves against MDA-MB-435S, HaCat and WRL-68 cell lines with IC50 values of 29.2, 30.1, and 52.4 μg/mL respectively.
Gavamukulya et al. (2014) investigated the cytotoxicity of the ethanol and aqueous extracts of A. muricata leaves on EACC, MDA, and SKBR3 tumor cell lines. The ethanol extracts showed IC50 values of 335.85, 248.77, and 202.33 μg/mL for EACC, MDA and SKBR3 tumor cell lines, respectively, and it showed no cytotoxic effect on normal spleen cells. The investigation also reported that the aqueous extract did not show any anticancer effect at all tested concentrations. Other than leaves, fruit, stems, and seeds of the A. muricata plant have also been reported to possess significant anticancer activities. In an in vitro study conducted on the fruit of A. muricata there was substantial repression of breast cancer cells growth (MDA-MB-468) as well as the selective suppression of the epidermal growth factor receptor (EGFR) (which regularly overexpressed in breast cancer) with IC50 of 4.8 μg/mL, while on non-tumorigenic human breast epithelial cells (MCF-10A) there was no effect (Dai et al., 2011). This promising investigation continued on mouse xenograft model and the results showed remarkable 56, 54, and 32.5% inhibition in protein expression of EGFR, p-EGFR, and p-ERK in MDA-MB-468 tumors, respectively, after 5 weeks of the administration of the A. muricata fruit extract (Dai et al., 2011). Recently, Sun et al. (2014) isolated and identified three novel annonaceous acetogenins, namely, muricin J, muricin K, and muricin L from the A. muricata fruit via chromatographic techniques and HPLC purification. These isolates were found to exhibit antiproliferative activity against human prostate cancer PC-3 cells. Apart from the leaves and fruits of the A. muricata, the stem also showed cytotoxic effect against various cell lines including U937, histiocytic lymphoma cell lines with IC50 of 10.5, 18.2, and 60.9 μg/ml exerted by the ethyl acetate, hexane and methanol extracts, respectively (Valencia et al., 2011). The stems also demonstrated cytotoxic activity by suppressing the expression of molecules associated to hypoxia and glycolysis in CD18/HPAF, pancreatic cancer cells (IC50:73.0 μg/mL) (Torres et al., 2012). Other than these, the ethanol extract of the seeds of A. muricata was also found to show cytotoxic effect on MDBK and HEp-2 cells (IC50 values: 34.5 and 55 mg/mL, respectively) at 24 h, and an IC50 value of 49.6 × 10−3 mg/mL toward HEp-2 cells at 72 h (Betancur-Galvis et al., 1999).
The hexane extract of the A. muricata leaves concentration-dependently inhibited the cell proliferation in pancreatic cancer cells (Capan-1) (Rosdi et al., 2015). Nineteen samples of A. muricata from different locations were screened against breast cancer cell lines; MCF-7, MDA-MB-231, and 4 T1. The results revealed that the aqueous extract of A. muricata leaves collected from Selangor, Malaysia showed the most potent effect with the lowest IC50 values of 220, 350 and 250 μg/mL for MCF7, MDA-MB231 and 4 T1 cell lines, respectively (Najmuddin et al., 2016). The extract also significantly decreased the size and weight of tumor, exhibited anti-metastatic properties, prompted apoptosis in vitro and in vivo of the 4 T1 cells as well as supressed the level of NO and malondialdehyde (MDA) in tumor while at the same time stimulated the level of white blood cell, T-cell, and natural killer cell population. Another study revealed that the chloroform, n-hexane and ethyl acetate extracts of the leaf of A. muricata possessed cytotoxic effect on Raji cells with IC50 values ranging from 90.6, 407.2 and 260.2 μg/mL. While, the cytotoxic effect of chloroform and n-hexane extracts on Hela cell gave IC50 values of 127.3 and 169.2 μg/mL, respectively (Artanti et al., 2016). Therefore it was confirmed from the aforesaid studies that the chloroform extract of the A. muricata leaves possessed potent cytotoxicity activity against Raji and Hela cells.
In Vivo Anticancer Activity of Extracts of A. muricata Leaves
Recently, it was reported that by modulating antioxidant enzymes in ICR male mice, the leaf extract of A. muricata caused blockage of 7, 12-dimethylbenz[a]anthracene (DMBA)/12-0- tetradecaboylphorbol-13-acetate (TPA)-induced skin tumorigenesis (Roduan et al., 2017). It was also explored that the hexane and dichloromethane extracts of the leaves of A. muricata incomparably blocked the tumor incidence as well as the tumor volume, while the methanol extract of the leaves displayed suppressive effects in comparison to carcinogen control group. In DMBA/TPA-induced mice, the administration of the leaf extract reduced the catalase, superoxide dismutase and lipid peroxidation levels to the normal levels (Roduan et al., 2017). Contrary to this, in DMBA-induced cell proliferation in the breast tissues of female albino mice, the ethanol extract of the A. muricata leaves exhibited chemo protective effect (Minari and Okeke, 2014). In addition, in rats, A. muricata leaves also demonstrated chemopreventive potential against azoxymethane-induced colonic aberrant crypt foci. (Moghadamtousi et al., 2015c). Another investigation reported that in liver cancer HepG2 cells, the ethanol extract of A. muricata leaves induced apoptosis through endoplasmic reticulum stress pathway (Liu et al., 2016). The proteomic analysis discovered 14 proteins associated with the extract in triggering apoptosis; including the up-regulation in HSP70, GRP94, and DPI-related protein 5 expression levels, which further confirmed the employment of the endoplasmic reticulum stress pathway by the extract. This investigation evidenced the potential of the A. muricata leaves extract as an effective anticancer agent. Subsequently, A. muricata extract was found to suppress the proliferation of HL-60 cells by inducing morphology changes, G0/G1 phase cell detention, damage to cell viability and detriment of membrane mitochondrial potential (Pieme et al., 2014). This finding proved that A. muricata has a promising potential as a chemotherapeutic agent to cure cancer. From all these findings, not only the leaves, the whole A. muricata plant parts were proven to be a versatile anticancer agent. Table 5 refers the key outcomes from prospective in vitro and in vivo oncogenic investigations on the various extracts of A. muricata leaves.
Table 5. Anticancer activity of A. muricata leaf extract.
Anticancer Activity of the Bioactive Isolates of A. muricata Leaves
Besides the findings generated from the crude extracts, further investigations have been conducted on the isolated bioactive compounds from the leaves of A. muricata, in order to have a detailed understanding of the mechanistic effects of the respective biological properties. However, only a few of the isolates have been investigated on their biological and pharmacological activities especially anti-inflammatory and anticancer activities. Table 6 lists the anticancer activity of the major bioactive isolates of A. muricata leaves. Annonaceous acetogenins, alkaloids, and phenols are the bioactive metabolites isolated from the A. muricata leaves, and among them, annonaceous acetogenins are the most predominant one. The annonaceous acetogenins are a class of natural products that distinctively belong to Annonaceae family. These bioactive compounds exhibited an array of bioactivities such as immunomodulatory, anti-inflammatory, anticancer, antiparasitic, insecticidal, antimicrobial, neurotoxic, antileishmaniasis, and antioxidant. The leaves, as well as the stems of A. muricata, exhibited active cytotoxicity against cancer cells, owing to these acetogenins, which did not show toxicity toward normal cells, but highly toxic to cancerous cells (Oberlies et al., 1995; Villo, 2008). Annonacin is the ubiquitous acetogenin present in A. muricata leaves (Yuan et al., 2003; Champy et al., 2004). The chemical structures of annonaceous acetogenins including annonacin and annomuricin E, isolated from the A. muricata leaves are shown in Figure 2.
Table 6. Anticancer activity of the major bioactive isolates of A. muricata leaves.
Figure 2. Structures of major bioactive isolates of Annona muricata leaves responsible for anticancer effects.
Annonacin
Yuan et al. (2003) reported annonacin (1), a mono-tetrahydrofuran acetogenin isolated from the seeds of A. reticulata, induced the cell cycle detention at the G1 phase in T24 bladder cancer cells by causing stimulation of p21, and also caused cytotoxicity in a Bax and caspase-3-related pathway. Subsequently, on 7, 12-dimethylbenz[a]anthracene (DMBA) induced and 12-0- tetradecaboylphorbol-13-acetate (TPA) promoted skin tumorigenesis in mice, the antitumor properties of different fractions of A. muricata leaves particularly hexane, dichloromethane, and methanol crude extracts were examined (Roduan et al., 2017). The outcomes of the experiment revealed the complete suppression of tumor formation in mice cured with the hexane and dichloromethane extracts of the leaves, respectively. While, the methanol extract showed significant delay in the tumor latency and attenuated the tumor incidence, tumor volume and tumor burden. Further investigation suggested that the hexane and dichloromethane extracts of the A. muricata leaves have higher content of annonacin. Therefore, the strong antitumor activity exerted by the extracts might be associated with the presence of cytotoxic constituents in the extracts particularly annonacin. The annonacin displayed its toxic effects on the cell by the suppression of mitochondrial complex I which resulted in the ATP depletion (Zafra-Polo et al., 1998; Yuan et al., 2003) and the repression of ubiquinone-linked NADH oxidase that is vital expression in cancer cells membrane which will kill the cancer cell and arrest the proliferation of cells (Woo et al., 1999). Besides, based on the study carried out by Ko et al. (2011), 0.1 μM of annonacin potentially induced growth arrest and apoptosis in ER-related pathways against MCF-7 cells.
Annomuricin E
The effects of the annomuricin E (2), an annonaceous acetogenin isolated from the ethyl acetate leaf extract of A.muricata on the HT-29 colon carcinoma cell lines and CCD841 normal colon cells were evaluated (Moghadamtousi et al., 2015c). Annomuricin E showed IC50 values of 5.72, 3.49, and 1.62 μg/mL for HT-29 cells, at time intervals of 12, 24, and 48 h of administrations, respectively. The results were found corresponding to the inhibitory potential exhibited by the standard anticancer drug used in the study, 5-FU. Annomuricin E showed a relatively high IC50 value for CCD841 with 32.51 μg/mL for 48 h, which demonstrated the lesser cytotoxic activities toward the normal cells. In addition, annomuricin E also prompted LDH leakage in HT-29 cells. The study reported that the annomuricin E increased the LDH leakage at concentration of 1 and 2 μg/mL and exhibited significant LDH release at the concentration from 4 to 16 μg/mL, parallel to the control cells, which were treated with 0.1% DMSO and displayed a low level of LDH after 24 h of treatment. The HT-29 cells showed significant LDH leakage at a dose of 4 μg/mL of annomuricin E. Annomuricin E, again proving its effectiveness as anticancer agent by inducing the cell cycle arrest at G1, the phosphatidylserine externalization (biochemical characterizations of apoptosis), the caspase activation, the mitochondria-initiated events, as well as Bax augmentation and Bcl-2 inhibition. All the data and parameters from the investigation conclude that annomuricin E inhibited the HT-29 cells proliferation selectively as well as prompted apoptosis, which is related to G1 cell cycle arrest and mitochondria-mediated signaling pathways.
Muricoreacin and Murihexocin C
Kim et al. (1998b) reported that both muricoreacin as well as murihexocin which were isolated from the 95% ethanol leaf extract A. muricata revealed substantial cytotoxic activities among six human tumor cells. Muricoreacin (3) was found particularly cytotoxic in contrast to the prostate adenocarcinoma (PC-3) cell line with 5 times higher activity compared to the positive antitumor control used, adriamycin. While, murihexocin C (4) showed selective cytotoxicity against the pancreatic carcinoma (PACA-2) as well as the prostate adenocarcinoma (PC-3) cell lines, with lower activity.
Other Biological Activities of Annona muricata Leaves
Besides the anti-inflammatory and anticancer properties, the leaves of A. muricata have also been thoroughly investigated for other pharmacological and biological properties. Bento et al. revealed that the A. muricata leaves showed significant antiulcer activity against lesions (Bento et al., 2016). Besides that, a remarkable wound healing properties by the ethyl acetate leaf extract of A. muricata has been discovered by Moghadamtousi et al. (2015b). In another investigation, the A. muricata leaves were showed to possess enzymatic antioxidants; superoxide dismutase and catalase, together with the non-enzymatic antioxidants for instance vitamin C and vitamin E (Vijayameena et al., 2013). The DPPH test revealed the significant antioxidant activity of the aqueous and ethanol extracts of A. muricata leaves (Gavamukulya et al., 2014). In addition, A. muricata leaves were also found to exhibit anti-plasmodial, anti-arthritic, anti-protozoal, antibacterial, antimicrobial, anticonvulsant, antidiabetic and hypolipidemic, antihypertensive, antiparasitic, insecticidal, gastroprotective, molluscicidal, hepatoprotective, and bilirubin-lowering activities (Moghadamtousi et al., 2015a).
Clinical Studies
At present, clinical trials on the standardized extract of A. muricata and its bioactive compounds may not be possible due to insufficient data generated from preclinical testings which include pharmacokinetic and toxicological studies. Despite the regulatory requirements for clinical studies, there were already two case studies carried out to evaluate the efficacy of A. muricata as an anticancer agent in human (Yap, 2013; Hansra et al., 2014). The first case involved a colon cancer patient who was subjected to combined lifestyle modifications with the intake of some herbal extracts and nutraceuticals, including a daily ingestion of 5 g of powdered leaf and seed of A. muricata extract. There was disappearance of the malignancy with substantial regression of colon tumor cells in the patient (Yap, 2013). Another study involved a breast cancer patient who was given 227 g of leaves decoction of A. muricata (10–12 dry leaves in water for 5–7 min) daily and capecitabina (2,500 mg PO) 2 weeks on 1 week off (Hansra et al., 2014). Tumor markers in the patient has been stable and had no side effects after therapy for 5 years. Since these are preliminary clinical trials with small sample size, more operationally thorough and serious randomized controlled trials have to be carried out to evaluate the plant as an effective and safe anti-inflammatory and anticancer agent for human consumption.
Toxicology Investigations
There are few data available on toxicity of A. muricata leaves and the data available are only on neurotoxicity and acute toxicity.
Neurotoxicity Studies
An epidemiological investigation was published by the Lancet Journal on possible relationship between atypical parkinsonism in the French West Indies with consumption of tropical fruits including A. muricata (Capparros-Lefebvre et al., 1999). The study postulated a link with consumption of herbal tea and fruits from the Annonaceae family (A. muricata and A. squamosa), which contain neurotoxic benzyltetrahydro-isoquinoline alkaloids, and Parkinson's disease. They suggested that chronic exposure to neurotoxic alkaloids could be an important aetiological factor because these compounds induce parkinsonism in animals. However, since this was a case-study involving small sample number (87 patients), a larger epidemiological study need to be carried out to clarify the link between these fruits with atypical parkinsonism and supranuclear palsy. This relationship has also been observed among New Caledonia and Caribbean patients living in London (Shaw and Hoglinger, 2008). Another study revealed that the ethiology of a neurodegenerative disease in Guadeloupe Island has a close correlation with consumption of annonaceous acetogenin. Annonacin present as the major compound depleted the ATP supply in rat striatal neurons and interrupted the transportation of mitochondria to the cell soma, which caused cellular pertubations in the protein tau and led to a number of similar characteristics as neurodegenerative diseases (Escobar-Khondiker et al., 2007). Bonneau et al. (2012) reported that annonaceous acetogenins were environmental neurotoxins responsible for Guadeloupean atypical Parkinsonism. The fruit of A. muricata was shown to contain high concentration of these compounds and its consumption constitute as a major source of exposure to these compounds and potential risk factors for neurodegeneration.
Quantification of acetogenins in A. muricata extracts by reversed phase HPLC and matrix-assisted laser desorption-ionization mass spectrometry (MALDI MS) showed an average A. muricata fruit contained about 15 mg of annonacin, a can of commercial nectar contained 36 mg, and a cup of infusion or decoction contained 140 μg (Champy et al., 2005). The neurotoxic effect of annonacin was determined by intravenous administration of annonacin (3.8 and 7.6 mg per kg per day for 28 days) to rats (Champy et al., 2004). Annonacin entered the brain parenchyma and decreased brain ATP levels by 44%, causing neuropathological abnormalities in the basal ganglia and brainstem nuclei. There was a significant loss of dopaminergic neurones in the substantia nigra, and cholinergic and dopamine and cyclic AMP-regulated phosphoprotein (DARPP-32)-immunoreactive GABAergic neurones in the striatum, accompanied by a significant increase in the number of astrocytes and microglial cells, based on stereological cell counts. The authors suggested that the distribution of the lesions was similar to that in patients with atypical parkinsonism. They also estimated that the amount of annonacin ingested in a year by eating one fruit or can of nectar a day were comparable to the dose of 3.8 mg/kg/day that induced widespread neurodegeneration when administered intravenously into rats for 28 days (106 mg/kg). However, without support of any bioavailability data on annonacin after intravenous or oral administration, this comparison was a crude estimation. Thus on the basis of available experimental data and the absence of detailed pharmacokinetic and pharmacodynamic data, preclinical and clinical studies, no confirmative conclusion on the link between consumption of A. muricata and atypical parkinsonism could be established yet. In 2010, l'Agence Francaise de Securite des Aliments (AVIS) issued a statement that it is not possible to conclude based on available experimental data that cases of atypical parkinsonism observed in Guadeloupe are linked to consumption of species belonging to Annonaceae family. However, it is advisable to avoid excessive and long term consumption of products containing A. muricata to prevent possible neurotoxicity.
Acute Toxicity Studies
de Sousa et al. (2010) reported that the ethanol extracts of A. muricata leaves exhibited LD50 value of 1.67 g/kg at the dosages of 0.5, 1, 1.5, 2, and 3 g/kg. While Larbie et al. (2011) reported that the intake of the aqueous extract exceeds 5 g/kg might caused kidney problem, however, 1 g/kg consumption of the extract exhibited hypoglycemic and hyperlipidemia effects. The previous investigations revealed that the methanol extracts of A. muricata pericarp, fruit pulp as well as the seeds were most toxic among the other parts of the plant (Boyom et al., 2011). On the other hand, Yang et al. (2015) have investigated the toxicity of A. muricata leaf extract together with its flavonoid- and acetogenins-enriched extracts and they revealed that the acetogenins-enriched extract was more toxic than the other extracts. Subsequently, Quilez et al. (2015) reported an acute toxicity study on the A. muricata leaves. The experiment was conducted using 5 week old Swiss albino male mice which were assigned randomly into a control group and three dosages groups with doses of 250–1,000 mg/kg. The animals were monitored 3 h after the treatment of the extract to observe any indication of toxicity or mortality, and then, for the next 48 h. The single dose of 250, 500, and 1,000 mg/kg did not show any behavioral changes in the treated animals and no mortality was reported during the study. The macroscopic pathology interpretations showed that there was no visible lesion in any treated animals. From the finding, it was confirmed that the A. muricata leaf extract did not show toxicity in the murine peritoneal macrophages by assessing with mitochondrial reduction of MTT (Quilez et al., 2015).
Conclusion & Future Prospects
Conclusively, A. muricata leaf and its secondary metabolites produce anti-inflammatory, anti-cancer and other immune system related effects. Literature reviews have identified and reported 117 isolates from the leaf of A. muricata, consisting mainly of annonaceous acetogenins, alkaloids, and phenolic compounds. In this review, we summarized versatile pharmacological activities particularly anti-inflammatory and anti-cancer effects possessed by aforesaid species. Still, there is much research gap and eventual studies need to be conducted for detailed investigations and better understanding of anti-inflammatory and anticancer potential exerted by A. muricata. In addition, most of the biological and pharmacological studies conducted using the crude extracts of the species are at its preliminary stages. The bioactive compounds contributing to the bioactivities have not been properly identified, qualitatively and quantitatively analyzed as chemical markers for standardization and quality control purposes as well as the mechanisms of action have not been well determined. Hence, future research on A. muricata should focus on extensive phytochemical investigations in isolating and identifying the active metabolites which contribute to the potent anti-inflammatory and anti-cancer activities. Subsequently, the extract and their active metabolites should also be subjected to more mechanistic studies, in vivo investigations in various animal models including pharmacokinetic and bioavailability studies. In addition, more toxicity studies must be conducted before submission to clinical trials to define the safest concentration of the A. muricata leaf to subjects. The potential of A. muricata leaves to be used as an anti-inflammatory and anticancer agent can clearly be enlightened by understanding its mechanisms of action on the human body system.
Author Contributions
SMAW drafted the manuscript. IJ participated in the concept, editing, and the final approval of the final version of the manuscript to be submitted for publication. MAH and LA were involved in the editing process.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
This work was supported by the Research University grant (Geran Universiti Penyelidikan) from Universiti Kebangsaan Malaysia (GUP-2017-027).
Abbreviations
ACF, colonic aberrant crypt foci; A. muricata, Annona muricata L.; ATP, adenosine triphosphate; DMBA, 2, 4-dimethoxybenzaldehyde; DPPH, 2, 2-diphenyl-1-picrylhydrazyl; ECM, extracellular matrix; EGFR, epidermal growth factor receptor; EGFR, epidermal growth factor receptor; ER, endoplasmic reticulum; ERK, extracellular signal-regulated kinases; 5-FU, fluorouracil; HPLC, high-performance liquid chromatography; HEp-2, human epithelial type 2 cells; Hsp70, 70 kilodalton heat shock protein; IL-1β, interleukin-1 beta; IL-6, interleukin-6; LPS, lipopolysaccharides; LDH, lactate dehydrogenase; MDBK, morphological observation of bovine kidney; MMPs, matrix metalloproteinases; MPO, myeloperoxidase; MTT, 3-(4, 5-dimethylthiazol-2-YI)-2, 5-diphenyltetrazolium bromide; NADH, nicotinamide adenine dinucleotide(NAD)+hydrogen(H); NO, nitric oxide; OECD, Organization for Economic Co-operation and Development; ROS, reactive oxygen species; TPA, tetradecanoylphorbol acetate; TNF-α, tumor necrosis factor-alpha; VCAM-1, vascular cell-adhesion molecule-1.
References
Abdillah, S., Tambunan, R. M., Farida, Y., Sandhiutami, N. M. D., and Dewi, R. M. (2015). Phytochemical screening and antimalarial activity of some plants traditionally used in Indonesia. Asian Pac. J. Trop. Dis. 5, 454–457. doi: 10.1016/S2222-1808(15)60814-3
Abdullah, M., Syam, A. F., Meilany, S., Laksono, B., Prabu, O. G., Bekti, H. S., et al. (2017). The value of caspase-3 after the application of Annona muricata leaf extract in COLO-205 colorectal cancer cell line. Gastroenterol. Res. Pract. 2017:4357165. doi: 10.1155/2017/4357165
Adewole, S. O., and Caxton-Martins, E. A. (2006). Morphological changes and hypoglycemic effects of Annona muricata linn.(Annonaceae) leaf aqueous extract on pancreatic β-cells of streptozotocin-treated diabetic rats. Afr. J. Biomed. Res. 9, 173–187. doi: 10.4314/ajbr.v9i3.48903
Adewole, S., and Ojewole, J. (2009). Protective effects of Annona muricata Linn.(Annonaceae) leaf aqueous extract on serum lipid profiles and oxidative stress in hepatocytes of streptozotocin-treated diabetic rats. Afr. J. Tradit. Complement. Altern. Med. 6, 30–41. doi: 10.1007/s11418-008-0298-0
Ahmad, W., Jantan, I., and Bukhari, S. N. (2016). Tinospora crispa (L.) Hook. f. & Thomson: a review of its ethnobotanical, phytochemical, and pharmacological aspects. Front. Pharmacol. 7:59. doi: 10.3389/fphar.2016.00059
Alali, F. Q., Liu, X.-X., and McLaughlin, J. L. (1999). Annonaceous acetogenins: recent progress. J. Nat. Prod. 62, 504–540. doi: 10.1021/np980406d
Alonso-Castro, A. J., Villarreal, M. L., Salazar-Olivo, L. A., Gomez-Sanchez, M., Dominguez, F., and Garcia-Carranca, A. (2011). Mexican medicinal plants used for cancer treatment: pharmacological, phytochemical and ethnobotanical studies. J. Ethnopharmacol. 133, 945–972. doi: 10.1016/j.jep.2010.11.055
Arshad, L., Haque, M. A., Abbas Bukhari, S. N., and Jantan, I. (2017a). An overview of structure-activity relationship studies of curcumin analogs as antioxidant and anti-inflammatory agents. Future Med. Chem. 9, 605–626. doi: 10.4155/fmc-2016-0223
Arshad, L., Jantan, I., Bukhari, S. N., and Haque, M. A. (2017b). Immunosuppressive effects of natural alpha,beta-unsaturated carbonyl-based compounds, and their analogs and derivatives, on immune cells: a review. Front. Pharmacol. 8:22. doi: 10.3389/fphar.2017.00022
Artanti, A. N., Astirin, O. P., and Prayitno, A. (2016). Cytotoxic activity of non polar fraction from Annona muricata L. leaves on Hela and Raji Cell Lines. J. Pharm. Sci. Clin. Res. 1, 112–118. doi: 10.20961/jpscr.v1i2.1944
Asare, G. A., Afriyie, D., Ngala, R. A., Abutiate, H., Doku, D., Mahmood, S. A., et al. (2015). Antiproliferative activity of aqueous leaf extract of Annona muricata L. on the prostate, BPH-1 cells, and some target genes. Integr. Cancer Ther. 14, 65–74. doi: 10.1177/1534735414550198
Asase, A., Hesse, D. N., and Simmonds, M. S. (2012). Uses of multiple plants prescriptions for treatment of malaria by some communities in southern Ghana. J. Ethnopharmacol. 144, 448–452. doi: 10.1016/j.jep.2012.09.028
Atawodi, S. E. (2011). Nigerian foodstuffs with prostate cancer chemopreventive polyphenols. Infect. Agents Cancer 6:S9. doi: 10.1186/1750-9378-6-S2-S9
Awan, J., Kar, A., and Udoudoh, P. (1980). Preliminary studies on the seeds of Annona muricata Linn. Plant. Foods Hum Nutr. 30, 163–168.
Balkwill, F. (2009). Tumor necrosis factor and cancer. Nat. Rev. Cancer 9, 5, 361–371. doi: 10.1038/nrc2628
Banerjee, A., Sengupta, A., Maji, B., Nandi, A., and Pal, S. (2017). Possible cytotoxic activity of Annona muricata Leaves in Huh-7 Human Liver Cancer Cells. J. Hepatol. 1:2.
Benavides González, A. (2011). Caracterización numérica de germoplasma de guanábana (Annona muricata L.) muestreado in situ en el pacífico y norte de Nicaragua. Revista La Calera 4, 29–35.
Bento, E. B., de Brito Júnior, F. E., de Oliveira, D. R., Fernandes, C. N., de Araújo Delmondes, G., Cesário, F. R. A. S., et al. (2016). Antiulcerogenic activity of the hydroalcoholic extract of leaves of Annona muricata Linnaeus in mice. Saudi J. Biol. Sci. 25, 609–621. doi: 10.1016/j.sjbs.2016.01.024
Betancur-Galvis, L. A., Saez, J., Granados, H., Salazar, A., and Ossa, J. E. (1999). Antitumor and antiviral activity of Colombian medicinal plant extracts. Mem. Inst. Oswaldo Cruz. 94, 531–535. doi: 10.1590/S0074-02761999000400019
Beyra, Á., León, M. D. C., Iglesias, E., Ferrándiz, D., Herrera, R., Volpato, G., et al. (2004). Estudios etnobotánicos sobre plantas medicinales en la provincia de Camagüey (Cuba). Anales Jard. Bot. Madrid. 61, 185–203.
Bonneau, N., Le Ven, J., Schmitz-Afonso, I., Guerineau, V., ba Ndob, I. B., Baloul, L., et al. (2012). Annonaceous acetogenins as environmental neurotoxins: human exposure from edible Annona fruits. Planta Med. 78:PH25. doi: 10.1055/s-0032-1320684
Boulogne, I., Germosén-Robineau, L., Ozier-Lafontaine, H., Fleury, M., and Loranger-Merciris, G. (2011). TRAMIL ethnopharmalogical survey in Les Saintes (Guadeloupe, French West Indies): a comparative study. J. Ethnopharmacol. 133, 1039–1050. doi: 10.1016/j.jep.2010.11.034
Boyom, F. F., Fokou, P. V. T., Yamthe, L. R. T., Mfopa, A. N., Kemgne, E. M., Mbacham, W. F., et al. (2011). Potent antiplasmodial extracts from Cameroonian Annonaceae. J. Ethnopharmacol. 134, 717–724. doi: 10.1016/j.jep.2011.01.020
Bradacs, G., Heilmann, J., and Weckerle, C. S. (2011). Medicinal plant use in vanuatu: a comparative ethnobotanical study of three islands. J. Ethnopharmacol. 137, 434–448. doi: 10.1016/j.jep.2011.05.050
Brechelt, A. (2004). El Manejo Ecológico de Plagas y Enfermedades. Red de Acción en Plaguicidas y sus Alternativas para América Latina (RAP-AL). Fundación Agricultura y Medio Ambiente (FAMA). RD.
Bussmann, R., Malca-García, G., Glenn, A., Sharon, D., Chait, G., Díaz, D., et al. (2010). Minimum inhibitory concentrations of medicinal plants used in Northern Peru as antibacterial remedies. J. Ethnopharmacol. 132, 101–108. doi: 10.1016/j.jep.2010.07.048
Capparros-Lefebvre, D., Elbaz, A., and Group, C. P. S. (1999). Possible relation of typical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Lancet 354, 281–286. doi: 10.1016/S0140-6736(98)10166-6
Cercato, L. M., White, P. A., Nampo, F. K., Santos, M. R., and Camargo, E. A. (2015). A systematic review of medicinal plants used for weight loss in Brazil: is there potential for obesity treatment? J. Ethnopharmacol. 176, 286–296. doi: 10.1016/j.jep.2015.10.038
Champy, P., Guérineau, V., and Laprévote, O. (2009). MALDI-TOF MS profiling of annonaceous acetogenins in Annona muricata products for human consumption. Molecules 14, 5235–5246. doi: 10.3390/molecules14125235
Champy, P., Höglinger, G. U., Féger, J., Gleye, C., Hocquemiller, R., Laurens, A., et al. (2004). Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J. Neurochem. 88, 63–69. doi: 10.1046/j.1471-4159.2003.02138.x
Champy, P., Melot, A., Guerineau Eng, V., Gleye, C., Fall, D., Hoglinger, G. U., et al. (2005). Quantificationof acetogenins in Annona muricata linked to atypical parkinsonism in guadeloupe. Mov. Disord. 20, 1629–1633. doi: 10.1002/mds.20632
Chan, P., Ah, R., and Mh, K. (2010). Anti-arthritic activities of Annona muricata L. leaves extract on complete Freund's adjuvant (CFA)–induced arthritis in rats. Planta Med. 76:P166. doi: 10.1055/s-0030-1264464
Chang, F.-R., Liaw, C.-C., Lin, C.-Y., Chou, C.-J., Chiu, H.-F., and Wu, Y.-C. (2003). New adjacent bis-tetrahydrofuran annonaceous acetogenins from Annona muricata. Planta Med. 69, 241–246. doi: 10.1055/s-2003-38485
Chettibi, S., Ferguson, M., Gallin, J., and Snyderman, R. (1999). Wound repair: an overview. Inflammation 3, 865–881.
Coe, F. G. (2008). Rama midwifery in eastern Nicaragua. J. Ethnopharmacol. 117, 136–157. doi: 10.1016/j.jep.2008.01.027
Coria-Téllez, A. V., Montalvo-Gónzalez, E., Yahia, E. M., and Obledo-Vázquez, E. N. (2016). Annona muricata: a comprehensive review on its traditional medicinal uses, phytochemicals, pharmacological activities, mechanisms of action and toxicity. Arabian J. Chem. doi: 10.1016/j.arabjc.2016.01.004
da Rocha, A. B., Lopes, R. M., and Schwartsmann, G. (2001). Natural products in anticancer therapy. Curr. Opin. Pharmacol. 1, 364–369. doi: 10.1016/S1471-4892(01)00063-7
Dagar, H., and Dagar, J. (1991). Plant folk medicines among the Nicobarese of Katchal Island, India. Econ. Bot. 45, 114–119. doi: 10.1007/BF02860056
Dai, Y., Hogan, S., Schmelz, E. M., Ju, Y. H., Canning, C., and Zhou, K. (2011). Selective growth inhibition of human breast cancer cells by graviola fruit extract in vitro and in vivo involving downregulation of EGFR expression. Nutr. Cancer 63, 795–801. doi: 10.1080/01635581.2011.563027
de Lima, M. C., and Alves, R. (2011). “Soursop (Annona muricata L.),” in Postharvest Biology and Technology of Tropical and Subtropical Fruits: Mangosteen to White Sapote ed E. Yahia (Sawston: Woodhead Publishing), 363–392e.
de Sousa, O. V., Vieira, G. D.-V., De Pinho, J. d. J. R., Yamamoto, C. H., and Alves, M. S. (2010). Antinociceptive and anti-inflammatory activities of the ethanol extract of Annona muricata L. leaves in animal models. Int. J. Mol. Sci. 11, 2067–2078. doi: 10.3390/ijms11052067
de Souza, R., Benassi, E., da Silva, R. R., Afonso, S., and Scarminio, I. S. (2009). Enhanced extraction yields and mobile phase separations by solvent mixtures for the analysis of metabolites in Annona muricata L. leaves. J. Sep. Sci. 32, 4176–4185. doi: 10.1002/jssc.200900375
DeFilipps, R. A., Maina, S. L., and Crepin, J. (2004). Medicinal Plants of the Guianas (Guyana, Surinam, French Guiana). Department of Botany, National Museum of Natural History, Smithsonian Institution Washington, DC.
Dey, A., Mukherjee, A., and Chaudhury, M. (2017). “Alkaloids from apocynaceae: origin, pharmacotherapeutic properties, and structure-activity studies,” in Studies in Natural Products Chemistry ed Atta-ur-Rahman (Amsterdam: Elsevier), 373–488.
Dvorak, H. F. (1986). Tumors: wounds that do not heal. New Eng. J. Med. 315, 1650–1659. doi: 10.1056/NEJM198612253152606
Escobar-Khondiker, M., Hollerhage, M., Muriel, M. –P., Champy, P., Bach, A., Depienne, C., et al. (2007). Annonacin, a natural mitochondrial complex I iunhibitor, causes tau pathology in cultured neurons. J. Neurosci. 27, 7827–7837. doi: 10.1523/JNEUROSCI.1644-07.2007
Ezirim, A., Okochi, V., James, A., Adebeshi, O., Ogunnowo, S., and Odeghe, O. (2013). Induction of apoptosis in myelogenous leukemic k562 cells by ethanolic leaf extract of Annona muricata L. Gjrmi 2:142.
Fang, X. P., Rieser, M. J., Gu, Z. M., Zhao, G. X., and McLaughlin, J. L. (1993). Annonaceous acetogenins: an updated review. Phytochem. Anal. 4, 27–48. doi: 10.1002/pca.2800040108
Feghali, C. A., and Wright, T. M. (1997). Cytokines in acute and chronic inflammation. Front. Biosci. 2:d12–d26. doi: 10.2741/A171
Feng, P. C., Haynes, L., Magnus, K. E., Plimmer, J., and Sherratt, H. (1962). Pharmacological screening of some West Indian medicinal plants. J. Pharm. Pharmacol. 14, 556–561. doi: 10.1111/j.2042-7158.1962.tb11139.x
Fofana, S., Keita, A., Balde, S., Ziyaev, R., and Aripova, S. (2012). Alkaloids from leaves of Annona muricata. Chem. Nat. Comp. 48, 714–714. doi: 10.1007/s10600-012-0363-5
Fofana, S., Ziyaev, R., Abdusamatov, A., and Zakirov, S. K. (2011). Alkaloids from Annona muricata leaves. Chem. Nat. Compd. 47, 321–321. doi: 10.1007/s10600-011-9921-5
Gavamukulya, Y., Abou-Elella, F., Wamunyokoli, F., and AEl-Shemy, H. (2014). Phytochemical screening, anti-oxidant activity and in vitro anticancer potential of ethanolic and water leaves extracts of Annona muricata (Graviola). Asian Pac. J. Trop. Med. 7, S355–S363. doi: 10.1016/S1995-7645(14)60258-3
Gavamukulya, Y., Wamunyokoli, F., and El-Shemy, H. A. (2017). Annona muricata: is the natural therapy to most disease conditions including cancer growing in our backyard? A systematic review of its research history and future prospects. Asian Pac. J. Trop. Med. 10, 835–848. doi: 10.1016/j.apjtm.2017.08.009
George, V. C., Kumar, D. N., Suresh, P., and Kumar, R. A. (2015). Antioxidant, DNA protective efficacy and HPLC analysis of Annona muricata (soursop) extracts. J. Food Sci. Technol. 52, 2328–2335. doi: 10.1007/s13197-014-1289-7
George, V. C., Kumar, D., Rajkumar, V., Suresh, P., and Kumar, R. A. (2012). Quantitative assessment of the relative antineoplastic potential of the n-butanolic leaf extract of Annona muricata Linn. in normal and immortalized human cell lines. Asian Pac. J. Cancer Prev. 13, 699–704. doi: 10.7314/APJCP.2012.13.2.699
González, B., Contreras, A. C., Lipcovich, J. Q., Centeno, D. M., and Carlos, J. (2004). Caracterización numérica de germoplasma de guanábana (Annona muricata L.) muestreado in situ en el Pacífico y Norte de Nicaragua. La Calera 10, 46–52.
Gupta, M. P., Arias, T. D., Correa, M., and Lamba, S. S. (1979). Ethnopharmacognostic observations on Panamanian medicinal plants. Part I. Q J. Crude Drug Res. 17, 115–130.
Haiat, S. W., and Bucay, J. W. (2009). Algunas plantas utilizadas en México para el tratamiento del asma. Anales de Otorrinolaringología. 54, 145–171.
Hajdu, Z., and Hohmann, J. (2012). An ethnopharmacological survey of the traditional medicine utilized in the community of Porvenir, Bajo Paraguá Indian Reservation, Bolivia. J. Ethnopharmacol. 139, 838–857. doi: 10.1016/j.jep.2011.12.029
Hamid, R. A., Foong, C. P., Ahmad, Z., and Hussain, M. K. (2012). Antinociceptive and anti-ulcerogenic activities of the ethanolic extract of Annona muricata leaf. Rev. Bras. Farmacogn. 22, 630–641. doi: 10.1590/S0102-695X2012005000001
Hamizah, S., Roslida, A., Fezah, O., Tan, K., Tor, Y., and Tan, C. (2012). Chemopreventive potential of Annona muricata L leaves on chemically-induced skin papillomagenesis in mice. Asian Pac. J. Cancer Prev. 13, 2533–2539. doi: 10.7314/APJCP.2012.13.6.2533
Hansra, D. M., Silva, O., Mehta, A., and Ahn, E. (2014). Patient with metastatic breast cancer achieves stable disease for 5 years on graviola and xeloda after progressing on multiple lines of therapy. Adv. Breast Cancer Res. 3, 84–87. doi: 10.4236/abcr.2014.33012
Haque, M. A., and Jantan, I. (2017). Recent updates on the Phytochemistry, Pharmacological, and toxicological activities of Zingiber zerumbet (L.) Roscoe ex Sm. Curr. Pharm. Biotechnol. 18, 696–720. doi: 10.2174/1389201018666171115115458
Haque, M. A., Jantan, I., and Abbas Bukhari, S. N. (2017a). Tinospora species: an overview of their modulating effects on the immune system. J. Ethnopharmacol. 207, 67–85. doi: 10.1016/j.jep.2017.06.013
Haque, M. A., Jantan, I., Arshad, L., and Bukhari, S. N. A. (2017b). Exploring the immunomodulatory and anticancer properties of zerumbone. Food Funct. 8, 3410–3431. doi: 10.1039/C7FO00595D
Harun, N. H., Septama, A. W., and Jantan, I. (2015). Immunomodulatory effects of selected Malaysian plants on the CD18/11a expression and phagocytosis activities of leukocytes. Asian Pac. J. Trop. Biomed. 5, 48–53. doi: 10.1016/S2221-1691(15)30170-2
Ilangkovan, M., Jantan, I., and Bukhari, S. N. A. (2016). Phyllanthin from Phyllanthus amarus inhibits cellular and humoral immune responses in Balb/C mice. Phytomedicine 23, 1441–1450. doi: 10.1016/j.phymed.2016.08.002
Ishola, I. O., Awodele, O., Olusayero, A. M., and Ochieng, C. O. (2014). Mechanisms of analgesic and anti-inflammatory properties of Annona muricata Linn. (Annonaceae) fruit extract in rodents. J. Med. Food 17, 1375–1382. doi: 10.1089/jmf.2013.0088
Isman, M. B., and Akhtar, Y. (2007). “Plant natural products as a source for developing environmentally acceptable insecticides,” in Insecticides Design Using Advanced Technologies, eds I, Ishaaya, F. Nauen, A. R Horowitz (Berlin; Heidelberg: Springer-Verlag Neitherland), 235–248.
Jantan, I., Ahmad, W., and Bukhari, S. N. (2015). Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials. Front. Plant Sci. 6:655. doi: 10.3389/fpls.2015.00655
Jaramillo-Flores, M. E., and Hernandez-Sanchez, H. (2000). Thermal diffusivity of soursop (Annona muricata L.) pulp. J. Food Eng. 46, 139–143. doi: 10.1016/S0260-8774(00)00074-1
Jiménez, V. M., Gruschwitz, M., Schweiggert, R. M., Carle, R., and Esquivel, P. (2014). Identification of phenolic compounds in soursop (Annona muricata) pulp by high-performance liquid chromatography with diode array and electrospray ionization mass spectrometric detection. Food Res. Int. 65, 42–46. doi: 10.1016/j.foodres.2014.05.051
Joyeux, M., Mortier, F., and Fleurentin, J. (1995). Screening of antiradical, antilipoperoxidant and hepatoprotective effects of nine plant extracts used in Caribbean folk medicine. Phytother. Res. 9, 228–230.
Karou, S. D., Tchacondo, T., Djikpo Tchibozo, M. A., Abdoul-Rahaman, S., Anani, K., Koudouvo, K., et al. (2011). Ethnobotanical study of medicinal plants used in the management of diabetes mellitus and hypertension in the Central Region of Togo. Pharm. Biol. 49, 1286–1297. doi: 10.3109/13880209.2011.621959
Kim, G., Tran, N., Choi, E., Song, Y., Song, J., Shim, S., et al. (2016), Immunomodulatory efficacy of standardized Annona muricata (Graviola) leaf extract via activation of mitogen-activated protein kinase pathways in RAW 264.7 macrophages. Evid. Based Complement. Altern. Med. 2016, 1–10. doi: 10.1155/2016/2905127
Kim, G.-S., Zeng, L., Alali, F., Rogers, L. L., Wu, F.-E., McLaughlin, J. L., et al. (1998a). Two new mono-tetrahydrofuran ring acetogenins, annomuricin E and muricapentocin, from the leaves of Annona muricata. J. Nat. Prod. 61, 432–436. doi: 10.1021/np970534m
Kim, G.-S., Zeng, L., Alali, F., Rogers, L. L., Wu, F.-E., Sastrodihardjo, S., et al. (1998b). Muricoreacin and murihexocin C, mono-tetrahydrofuran acetogenins, from the leaves of Annona muricata in honour of professor GH Neil Towers 75th birthday. Phytochemistry 49, 565–571. doi: 10.1016/S0031-9422(98)00172-1
Ko, Y. M., Wu, T. Y., Wu, Y. C., Chang, F. R., Guh, J. Y., and Chuang, L. Y. (2011). Annonacin induces cell cycle-dependent growth arrest and apoptosis in estrogen receptor-α-related pathways in MCF-7 cells. J. Ethnopharmacol. 137, 1283–1290. doi: 10.1016/j.jep.2011.07.056
Konno, H., Okuno, Y., Makabe, H., Nosaka, K., Onishi, A., Abe, Y., et al. (2008). Total synthesis of cis-solamin A, a mono-tetrahydrofuran acetogenin isolated from Annona muricata. Tetrahedron Lett. 49, 782–785. doi: 10.1016/j.tetlet.2007.11.190
Kossouoh, C., Moudachirou, M., Adjakidje, V., Chalchat, J.-C., and Figuérédo, G. (2007). Essential oil chemical composition of Annona muricata L. leaves from Benin. J. Essent. Oil Res. 19, 307–309. doi: 10.1080/10412905.2007.9699288
Kotake, Y., Okuda, K., Kamizono, M., Matsumoto, N., Tanahashi, T., Hara, H., et al. (2004). Detection and determination of reticuline and N-methylcoculaurine in the Annonaceae family using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 806, 75–78. doi: 10.1016/j.jchromb.2004.03.017
Laksmitawati, D. R., Prasanti, A. P., Larasinta, N., Syauta, G. A., Hilda, R., Ramadaniati, H. U., et al. (2016). Anti-Inflammatory potential of gandarusa (Gendarussa vulgaris Nees) and soursoup (Annona muricata L) extracts in LPS stimulated-macrophage cell (RAW264. 7). J. Nat. Rem. 16, 73–81. doi: 10.18311/jnr/2016/5367
Langenberger, G., Prigge, V., Martin, K., Belonias, B., and Sauerborn, J. (2009). Ethnobotanical knowledge of Philippine lowland farmers and its application in agroforestry. Agrofor. Syst. 76, 173–194. doi: 10.1007/s10457-008-9189-3
Lans, C. A. (2006). Ethnomedicines used in Trinidad and Tobago for urinary problems and diabetes mellitus. J. Ethnobiol. Ethnomed. 2:45. doi: 10.1186/1746-4269-2-45
Larbie, C., Arthur, W. E., and Terlabi, E. (2011). Evaluation of acute and subchronic toxicity of Annona muricata (Linn) aqueous extract in animal. J. Exp. Bot. 1, 115–124.
Leatemia, J. A., and Isman, M. B. (2004). Insecticidal activity of crude seed extracts of Annona spp., Lansium domesticum and Sandoricum koetjape against lepidopteran larvae. Phytoparasitica 32, 30–37. doi: 10.1007/BF02980856
Leboeuf, M., Caré, A., Tohami, M. E., Pusset, J., Forgacs, P., and Provost, J. (1982). Alkaloids of Annonaceae. XXXV. alkaloids of Desmos tiebaghiensis. J. Nat. Prod. 45, 617–623. doi: 10.1021/np50023a017
Leboeuf, M., Cavé, A., Bhaumik, P., Mukherjee, B., and Mukherjee, R. (1980). The phytochemistry of the Annonaceae. Phytochemistry 21, 2783–2813. doi: 10.1016/0031-9422(80)85046-1
Leboeuf, M., Legueut, C., Cavé, A., Desconclois, J., Forgacs, P., and Jacquemin, H. (1981). Alcaloïdes des Annonacées XXIX: Alcaloïdes de l'Annona muricata L. Planta Med. 42, 37–44. doi: 10.1055/s-2007-971543
Liaw, C.-C., Chang, F.-R., Lin, C.-Y., Chou, C.-J., Chiu, H.-F., Wu, M.-J., et al. (2002). New cytotoxic monotetrahydrofuran annonaceous acetogenins from Annona muricata. J. Nat. Prod. 65, 470–475. doi: 10.1021/np0105578
Liu, N., Yang, H. L., Wang, P., Lu, Y. C., Yang, Y. J., Wang, L., et al. (2016). Functional proteomic analysis revels that the ethanol extract of Annona muricata L. induces liver cancer cell apoptosis through endoplasmic reticulum stress pathway. J. Ethnopharmacol. 189, 210–217. doi: 10.1016/j.jep.2016.05.045
Longuefosse, J.-L., and Nossin, E. (1996). Medical ethnobotany survey in Martinique. J. Ethnopharmacol. 53, 117–142. doi: 10.1016/0378-8741(96)01425-0
Marques, V., and Farah, A. (2009). Chlorogenic acids and related compounds in medicinal plants and infusions. Food Chem. 113, 1370–1376. doi: 10.1016/j.foodchem.2008.08.086
Matsushige, A., Kotake, Y., Matsunami, K., Otsuka, H., Ohta, S., and Takeda, Y. (2012a). Annonamine, a new aporphine alkaloid from the leaves of Annona muricata. Chem. Pharm. Bull. 60, 257–259. doi: 10.1248/cpb.60.257
Matsushige, A., Matsunami, K., Kotake, Y., Otsuka, H., and Ohta, S. (2012b). Three new megastigmanes from the leaves of Annona muricata. J. Nat. Med. 66, 284–291. doi: 10.1007/s11418-011-0583-1
Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature 454, 428–435. doi: 10.1038/nature07201
Ménan, H., Banzouzi, J.-T., Hocquette, A., Pélissier, Y., Blache, Y., Koné, M., et al. (2006). Antiplasmodial activity and cytotoxicity of plants used in West African traditional medicine for the treatment of malaria J. Ethnopharmacol. 105, 131–136. doi: 10.1016/j.jep.2005.10.027
Minari, J., and Okeke, U. (2014). Chemopreventive effect of Annona muricata on DMBA-induced cell proliferation in the breast tissues of female albino mice. Egypt. J. Med. Human Gene. 15, 327–334. doi: 10.1016/j.ejmhg.2014.05.001
Mishra, S., Ahmad, S., Kumar, N., and Sharma, B. (2013). Annona muricata (the cancer killer): a review. Glob. J. Pharm. Res. 2, 1613–1618.
Moghadamtousi, S. Z., Fadaeinasab, M., Nikzad, S., Mohan, G., Ali, H. M., and Kadir, H. A. (2015a). Annona muricata (Annonaceae): a review of its traditional uses, isolated acetogenins and biological activities. Int. J. Mol. Sci. 16, 15625–15658. doi: 10.3390/ijms160715625
Moghadamtousi, S. Z., Karimian, H., Rouhollahi, E., Paydar, M., Fadaeinasab, M., and Kadir, H. A. (2014). Annona muricata leaves induce G 1 cell cycle arrest and apoptosis through mitochondria-mediated pathway in human HCT-116 and HT-29 colon cancer cells. J. Ethnopharmacol. 156, 277–289. doi: 10.1016/j.jep.2014.08.011
Moghadamtousi, S. Z., Rouhollahi, E., Hajrezaie, M., Karimian, H., Abdulla, M. A., and Kadir, H. A. (2015b). Annona muricata leaves accelerate wound healing in rats via involvement of Hsp70 and antioxidant defence. Int. J. Surg. 18, 110–117. doi: 10.1016/j.ijsu.2015.03.026
Moghadamtousi, S. Z., Rouhollahi, E., Karimian, H., Fadaeinasab, M., Firoozinia, M., Abdulla, M. A., et al. (2015c). The chemopotential effect of Annona muricata leaves against azoxymethane-induced colonic aberrant crypt foci in rats and the apoptotic effect of acetogenin annomuricin E in HT-29 cells: a bioassay-guided approach. PLoS ONE 10:e0122288. doi: 10.1371/journal.pone.0122288
Mohamed, S. I. A., Jantan, I., and Haque, M. A. (2017). Naturally occurring immunomodulators with antitumor activity: an insight on their mechanisms of action. Int. Immunopharmacol. 50, 291–304. doi: 10.1016/j.intimp.2017.07.010
Mohammed, M. T., and Abbas, S. I. (2016). Antioxidant and anti-inflammatory effect of fruit juice of Annona muricata L (Soursop) during ischemia reperfusion injury in rats. Iraqi Postgrad. Med. J. 15, 118–123.
Mohanty, S., Hollinshead, J., Jones, L., Jones, P. W., Thomas, D., Watson, A. A., et al. (2008). Annona muricata (Graviola): Toxic or therapeutic. Nat. Prod. Commun. 3, 31–33.
Monigatti, M., Bussmann, R. W., and Weckerle, C. S. (2013). Medicinal plant use in two Andean communities located at different altitudes in the Bolívar Province, Peru. J. Ethnopharmacol. 145, 450–464. doi: 10.1016/j.jep.2012.10.066
Mootoosamy, A., and Mahomoodally, M. F. (2014). Ethnomedicinal application of native remedies used against diabetes and related complications in Mauritius. J. Ethnopharmacol. 151, 413–444. doi: 10.1016/j.jep.2013.10.069
Najmuddin, S. U. F. S., Romli, M. F., Hamid, M., Alitheen, N. B., and Rahman, N. M. A. N. A. (2016). Anti-cancer effect of Annona muricata Linn leaves crude extract on breast cancer cell line. BMC Complement. Altern. Med. 16:311. doi: 10.1186/s12906-016-1290-y
Nakanishi, Y., Chang, F.-R., Liaw, C.-C., Wu, Y.-C., Bastow, K. F., and Lee, K.-H. (2003). Acetogenins as selective inhibitors of the human ovarian 1A9 tumor cell line 1. J. Med. Chem. 46, 3185–3188. doi: 10.1021/jm020548b
Nawwar, M., Ayoub, N., Hussein, S., Hashim, A., El-Sharawy, R., Wende, K., et al. (2012). Flavonol triglycoside and investigation of the antioxidant and cell stimulating activities of Annona muricata Linn. Arch. Pharm. Res. 35, 761–767. doi: 10.1007/s12272-012-0501-4
Nguyen-Pouplin, J., Tran, H., Tran, H., Phan, T. A., Dolecek, C., Farrar, J., et al. (2007). Antimalarial and cytotoxic activities of ethnopharmacologically selected medicinal plants from South Vietnam. J. Ethnopharmacol. 109, 417–427. doi: 10.1016/j.jep.2006.08.011
Novy, J. W. (1997). Medicinal plants of the eastern region of Madagascar. J. Ethnopharmacol. 55, 119–126. doi: 10.1016/S0378-8741(96)01489-4
Oberlies, N. H., Jones, J. L., Corbett, T. H., Fotopoulos, S. S., and McLaughlin, J. L. (1995). Tumor cell growth inhibition by several annonaceous acetogenins in an in vitro disk diffusion assay. Cancer Lett. 96, 55–62. doi: 10.1016/0304-3835(95)92759-7
Ong, H. G., and Kim, Y.-D. (2014). Quantitative ethnobotanical study of the medicinal plants used by the Ati Negrito indigenous group in Guimaras island, Philippines. J. Ethnopharmacol. 157, 228–242. doi: 10.1016/j.jep.2014.09.015
Ong, H., and Norzalina, J. (1999). Malay herbal medicine in Gemencheh, Negri Sembilan, Malaysia. Fitoterapia 70, 10–14. doi: 10.1016/S0367-326X(98)00023-9
Osorio, E., Arango, G. J., Jiménez, N., Alzate, F., Ruiz, G., Gutiérrez, D., et al. (2007). Antiprotozoal and cytotoxic activities in vitro of Colombian Annonaceae. J. Ethnopharmacol. 111, 630–635. doi: 10.1016/j.jep.2007.01.015
Oviedo, V., García, M., Díaz, C., Costa, M., Rincón, J., Sánchez, C., et al. (2009). Extracto y fracción alcaloidal de Annona muricata con actividad de tipo ansiolítica en ratones. Rev. Colomb. Cienc. Quím.-Farm. 38, 105–120.
Paulinus, O., Kinsley, A., and Ikechi, E. (2013). Protective effect of ethanolic leaf extract of Annona muricata Linn. on some early events in cycas induced colorectal carcinogenesis in rats. J. Pharm. Sci. Innov. 2, 14–21. doi: 10.7897/2277-4572.02444
Pieme, C. A., Kumar, S. G., Dongmo, M. S., Moukette, B. M., Boyoum, F. F., Ngogang, J. Y., et al. (2014). Antiproliferative activity and induction of apoptosis by Annona muricata (Annonaceae) extract on human cancer cells. BMC Complement. Altern. Med. 14:516. doi: 10.1186/1472-6882-14-516
Pinto, A. d. Q., Cordeiro, M. C. R., De Andrade, S., Ferreira, F. R., Filgueiras, H. d. C., Alves, R., et al. (2005b). Annona Species. International Centre for Underutilised Crops; Southampton
Pinto, A. Q., Cordeiro, M., De Andrade, S., Ferreira, F., Filgueiras, H., and Alves, R. (2005a). Annona Species. International Centre for Underutilized Crops. Southampton.
Poma, E. M., Requis, E. R., Gordillo, G. C., and Fuertes, C. M. (2011). Estudio fitoquímico y actividad antiinflamatoria de la Annona muricata L. (guanábana) de Cuzco. Cienc E Investig. 14, 29–33.
Quilez, A., Montserrat-de la Paz, S., De la Puerta, R., Fernández-Arche, M., and García-Giménez, M. (2015). Validation of ethnopharmacological use as anti-inflammatory of a decoction from Annona muricata leaves. Afr. J. Tradit. Complement. Altern. Med. 12, 14–20. doi: 10.4314/ajtcam.v12i4.3
Quispe, A., Zavala, D., Rojas, J., Posso, M., and Vaisberg, A. (2006). Efecto citotóxico selectivo in vitro de muricin H (acetogenina de Annona muricata) en cultivos celulares de cáncer de pulmón. Rev. Peru Med. Exp. Salud. 23, 265–269.
Rai, P., Matainaho, T., Saulei, S., and Ambihaipahar, U. (2009). Medicinal Plants in Papua New Guinea. Parts I & II.
Ritter, R. A., Monteiro, M. V. B., Monteiro, F. O. B., Rodrigues, S. T., Soares, M. L., Silva, J. C. R., et al. (2012). Ethnoveterinary knowledge and practices at Colares island, Pará state, eastern Amazon, Brazil. J. Ethnopharmacol. 144, 346–352. doi: 10.1016/j.jep.2012.09.018
Rodríguez, M. (2011). Manejo de plantas medicinales en el nororiente amazónico peruano. Rev Eciperú 8, 150–158.
Roduan, M. R. M., Hamid, R. A., Sulaiman, H., and Mohtarrudin, N. (2017). Annona muricata leaves extracts prevent DMBA/TPA-induced skin tumorigenesis via modulating antioxidants enzymes system in ICR mice. Biomed. Pharmacother. 94, 481–488. doi: 10.1016/j.biopha.2017.07.133
Roger, T., Pierre-Marie, M., Igor, V. K., and Patrick, V. D. (2015). Phytochemical screening and antibacterial activity of medicinal plants used to treat typhoid fever in Bamboutos division, West Cameroon. J. Appl. Pharm. Sci. 5, 34–49. doi: 10.7324/JAPS.2015.50606
Roosita, K., Kusharto, C. M., Sekiyama, M., Fachrurozi, Y., and Ohtsuka, R. (2008). Medicinal plants used by the villagers of a Sundanese community in West Java, Indonesia. J. Ethnopharmacol. 115, 72–81. doi: 10.1016/j.jep.2007.09.010
Rosdi, M. N. M., Daud, N. N. N. N. M., Zulkifli, R. M., and Ya'akob, H. (2015). Cytotoxic effect of Annona muricata Linn leaves extract on Capan-1 cells. Pharm. Sci. 5, 045–048. doi: 10.7324/JAPS.2015.50508
Shaw, C. A., and Hoglinger, G. U. (2008). Neurodegenerative diseases: neurotoxins as sufficient etiologic agents. Neuro. Mol. Med. 10, 1–9. doi: 10.1007/s12017-007-8016-8
Sotheeswaran, S., Doyle, M., and Aalbersberg, W. G. (1998). Medicinal Plants in the South Pacific. WHO, Regional office for the Western Pacific.
Sreekeesoon, D. P., and Mahomoodally, M. F. (2014). Ethnopharmacological analysis of medicinal plants and animals used in the treatment and management of pain in Mauritius. J. Ethnopharmacol. 157, 181–200. doi: 10.1016/j.jep.2014.09.030
Ssenyange, C. W., Namulindwa, A., Oyik, B., and Ssebuliba, J. (2015). Plants used to manage type II diabetes mellitus in selected districts of central Uganda. Afr. Health Sci. 15, 496–502. doi: 10.4314/ahs.v15i2.24
Sulistyoningrum, E., Rachmani, E. P. N., Baroroh, H. N., and Rujito, L. (2017). Annona muricata leaves extract reduce proliferative indexes and improve histological changes in rat's breast cancer. J. Appl. Pharm. Sci. 7, 149–155. doi: 10.7324/JAPS.2017.70120
Sun, S., Liu, J., Kadouh, H., Sun, X., and Zhou, K. (2014). Three new anti-proliferative Annonaceous acetogenins with mono-tetrahydrofuran ring from graviola fruit (Annona muricata). Bioorganic Med. Chem. Lett. 24, 2773–2776. doi: 10.1016/j.bmcl.2014.03.099
Sun, S., Liu, J., Zhou, N., Zhu, W., Dou, Q. P., and Zhou, K. (2016). Isolation of three new annonaceous acetogenins from graviola fruit (Annona muricata) and their anti-proliferation on human prostate cancer cell PC-3. Bioorganic Med. Chem. Lett. 26, 4382–4385. doi: 10.1016/j.bmcl.2015.06.038
Tan, L. T. H., Lee, L. H., Yin, W. F., Chan, C. K., Abdul Kadir, H., Chan, K. G., et al. (2015). Traditional uses, phytochemistry, and bioactivities of Cananga odorata (ylang-ylang). Evid. Based Complement. Alternat. Med. 2015:896314. doi: 10.1155/2015/896314
Taylor, L. (2002). Graviola. Technical data report for graviola, Annona muricata. Sage Press, Austin.
Tene, V., Malagon, O., Finzi, P. V., Vidari, G., Armijos, C., and Zaragoza, T. (2007). An ethnobotanical survey of medicinal plants used in Loja and Zamora-Chinchipe, Ecuador. J. Ethnopharmacol. 111, 63–81. doi: 10.1016/j.jep.2006.10.032
Torres, M. P., Rachagani, S., Purohit, V., Pandey, P., Joshi, S., Moore, E. D., et al. (2012). Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer lett. 323, 29–40. doi: 10.1016/j.canlet.2012.03.031
Tsabang, N., Fokou, P. V. T., Tchokouaha, L. R. Y., Noguem, B., Bakarnga-Via, I., Nguepi, M. S. D., et al. (2012). Ethnopharmacological survey of Annonaceae medicinal plants used to treat malaria in four areas of Cameroon. J. Ethnopharmacol. 139, 171–180. doi: 10.1016/j.jep.2011.10.035
Valencia, L., Muñoz, D. L., Robledo, S. M., Echeverri, F., Arango, G. J., Vélez, I. D., et al. (2011). Actividad tripanocida y citotóxica de extractos de plantas colombianas. Biomédica 31, 552–559.
Vandebroek, I., Balick, M. J., Ososki, A., Kronenberg, F., Yukes, J., Wade, C., et al. (2010). The importance of botellas and other plant mixtures in Dominican traditional medicine. J. Ethnopharmacol. 128, 20–41. doi: 10.1016/j.jep.2009.12.013
Vijayameena, C., Subhashini, G., Loganayagi, M., and Ramesh, B. (2013). Phytochemical screening and assessment of antibacterial activity for the bioactive compounds in Annona muricata. Int. J. Curr. Microbiol. Appl. Sci. 2, 1–8.
Watt, J. M., and Breyer-Brandwijk, M. G. (1962). The Medicinal and Poisonous Plants of Southern and Eastern Africa Being an Account of Their Medicinal and Other Uses, Chemical Composition, Pharmacological Effects and Toxicology in Man and Animal. E. & S. Livingstone Ltd.
Woo, M.-H., Chung, S.-O., and Kim, D.-H. (1999). cis-Annonacin and (2, 4)-cis-andtrans-isoannonacins: cytotoxic monotetrahydrofuran annonaceous acetogenins from the seeds ofAnnona cherimolia. Arch. Pharm. Res. 22, 524–528. doi: 10.1007/BF02979164
Wu, F.-E., Gu, Z.-M., Zeng, L., Zhao, G.-X., Zhang, Y., McLaughlin, J. L., et al. (1995a). Two new cytotoxic monotetrahydrofuran Annonaceous acetogenins, annomuricins A and B, from the leaves of Annona muricata. J. Nat. Prod. 58, 830–836. doi: 10.1021/np50120a002
Wu, F.-E., Zeng, L., Gu, Z.-M., Zhao, G.-X., Zhang, Y., Schwedler, J. T., et al. (1995b). Muricatocins A and B, two new bioactive monotetrahydrofuran Annonaceous acetogenins from the leaves of Annona muricata. J. Nat. Prod. 58, 902–908. doi: 10.1021/np50120a013
Wu, F.-E., Zhao, G.-X., Zeng, L., Zhang, Y., Schwedler, J. T., McLaughlin, J. L., et al. (1995c). Additional bioactive acetogenins, annomutacin and (2, 4-trans and cis)-10R-annonacin-A-ones, from the leaves of Annona muricata. J. Nat. Prod. 58, 1430–1437. doi: 10.1021/np50123a015
Yang, C., Gundala, S. R., Mukkavilli, R., Vangala, S., Reid, M. D., and Aneja, R. (2015). Synergistic interactions among flavonoids and acetogenins in Graviola (Annona muricata) leaves confer protection against prostate cancer. Carcinogenesis 36, 656–665. doi: 10.1093/carcin/bgv046
Yap, S. (2013). Colon cancer reversed by phyto-nutritional therapy: a case study. Int. J. Biotechnol. Wellness Ind. 2, 132–139. doi: 10.6000/1927-3037.2013.02.03.4
Yasunaka, K., Abe, F., Nagayama, A., Okabe, H., Lozada-Pérez, L., López-Villafranco, E., et al. (2005). Antibacterial activity of crude extracts from Mexican medicinal plants and purified coumarins and xanthones. J. Ethnopharmacol. 97, 293–299. doi: 10.1016/j.jep.2004.11.014
Yu, J., Gui, H., Luo, X., Sun, L., Zhu, P., and Yu, Z. (1997). Studies on the chemical constituents of Annona muricata. Yao Xue Xue Bao 32, 431–437.
Yuan, S.-S. F., Chang, H.-L., Chen, H.-W., Yeh, Y.-T., Kao, Y.-H., Lin, K.-H., et al. (2003). Annonacin, a mono-tetrahydrofuran acetogenin, arrests cancer cells at the G1 phase and causes cytotoxicity in a Bax-and caspase-3-related pathway. Life Sci. 72, 2853–2861. doi: 10.1016/S0024-3205(03)00190-5
Zafra-Polo, M. C., Figadère, B., Gallardo, T., Tormo, J., and Cortes, D. (1998). Natural acetogenins from Annonaceae, synthesis and mechanisms of action. Phytochemistry 48, 1087–1117. doi: 10.1016/S0031-9422(97)00917-5
Keywords: Annona muricata leaves, phytochemistry, anti-inflammatory effects, anticancer effects, neurotoxic acetogenins
Citation: Abdul Wahab SM, Jantan I, Haque MA and Arshad L (2018) Exploring the Leaves of Annona muricata L. as a Source of Potential Anti-inflammatory and Anticancer Agents. Front. Pharmacol. 9:661. doi: 10.3389/fphar.2018.00661
Received: 22 December 2017; Accepted: 01 June 2018;
Published: 20 June 2018.
Edited by:
Marco Leonti, Università degli studi di Cagliari, ItalyReviewed by:
Sevser Sahpaz, Lille University, FranceAnastasia Karioti, Aristotle University of Thessaloniki, Greece
Copyright © 2018 Abdul Wahab, Jantan, Haque and Arshad. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ibrahim Jantan, profibj@gmail.com